Weinrich, Scott L.
Pfizer (United States) · WuXi AppTec (China)
6 papers on CoChat
Most cited papers
- Verified
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science
Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms
Cited by 7,091
- Verified
Telomerase Catalytic Subunit Homologs from Fission Yeast and Human
Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., & Cech, T. R. (1997) · Science
Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms
Cited by 2,256
- Verified
The RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science
Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms
Cited by 2,227
- Verified
Telomerase, Cell Immortality, and Cancer
Harley, C. B., Kim, N. W., Prowse, K. R., Weinrich, S. L., Hirsch, K. S., West, M. D., Bacchetti, S., Hirte, H. W., Counter, C. M., Greider, C. W., et al. (1994) · Cold Spring Harbor Symposia on Quantitative Biology
Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms
Cited by 396
- Verified
Identification of a Poor-Prognosis BRAF-Mutant–Like Population of Patients With Colon Cancer
Popovici, V., Budinska, E., Tejpar, S., Weinrich, S., Estrella, H., Hodgson, G., Van Cutsem, E., Xie, T., Bosman, F. T., Roth, A. D., et al. (2012) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 236
- Verified
Discovery of N-((3 R,4 R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1 H-pyrazol-4-yl)amino)-9-methyl-9 H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR
Planken, S., Behenna, D. C., Nair, S. K., Johnson, T. O., Nagata, A., Almaden, C., Bailey, S., Ballard, T. E., Bernier, L., Cheng, H., et al. (2017) · Journal of Medicinal Chemistry
Lung Cancer Treatments and MutationsComputational Drug Discovery Methods
Cited by 97
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free